載入中
NASDAQHealthcareBiotechnology
最新資料
US$5.38
+US$0.11 · +2.09%
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
前收盤價
US$5.38
+US$0.11 · +2.09%
盤中時間採用ET。市場資料可能有所延遲。
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
日內區間
目前US$5.38
52週區間
目前US$5.38
盤中時間採用ET。市場資料可能有所延遲。
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
日內區間
目前US$5.38
52週區間
目前US$5.38
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$33.67
上漲空間 525.84%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2023年2月14日 | 1:30 | — | — |
已生效 2023年2月14日
1:30
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI582.13萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM231.17萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF215.63萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO103.31萬0.01%180億 USD0.06%US$112.66+0.50%
Dimensional - US Small Cap ETFDFAS52.53萬0.00%338.69億 USD0.31%US$78.35+0.32%
Fidelity Enhanced Small Cap ETFFESM48.27萬0.01%64.1億 USD0.28%US$45.46+0.46%
iShares Micro-Cap ETFIWC28.42萬0.02%13.17億 USD0.60%US$183+0.11%
U.S. Micro Cap Portfolio ETFDFMC20.93萬0.00%75.58億 USD0.43%US$57.813+0.20%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASFidelity Enhanced Small Cap ETFFESMiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
